Pharmacogenetic testing is gaining momentum as a powerful tool in optimizing employee health and productivity, and managing disability and absenteeism
Pharmacogenetic testing can help your plan members with pain or mental health conditions find the right treatment faster
With only one third of patients responding well to the first drug prescribed to them, most plan members will spend weeks or months trialling different medications, often enduring side effects along with the persistent symptoms of their condition. Even worse, the chances of remission decrease with each subsequent drug trialled.
Sub-optimal drug experiences can drive adherence issues and resistance to trying new medications, perpetuating disability. Other consequences can include worsening of symptoms/condition, polypharmacy, and risk of drug dependency.
The good news?
Genetic factors are estimated to drive approximately 60% of individual drug response variability (20 – 95% depending on the drug). 1-4 Knowing what genetic variants your plan members carry and how this impacts which drugs will work best for them puts them in the driver's seat, empowered with a personalized road map to better health.
Ensuring the right drugs are prescribed for plan members at the outset arms plan managers with a powerful tool to support member well being, reduce absenteeism, and disability, and control drug costs.
Guiding treatment based on pharmacogenetic testing has been shown to reduce drug wastage, overall healthcare costs, and lost productivity,5-9 while driving powerful clinical results:
A medication change for 45% 10
A dosage change for 30% 10
30% reduction in pain 11
50% reduction in opioid usage post surgery 12
2X the response rates 13, 14
4X the symptom improvement 13, 14
1.7X the remission rates
(mental health) 13, 14
40% fewer ER visits
58% fewer hospitalizations 15
Plan members rank pharmacogenetic testing as a "Top 10 Product" in 2020 16
The 2020 Sanofi Healthcare Report revealed that plan members would like to see pharmacogenetic testing offered as part of their benefit plans (ranking as #8 of the top 10 products listed).
Offering pharmacogenetic testing empowers and engages plan members to take control of their own health, promoting a culture of well-being while supporting employee engagement and productivity.
Re-energize Group Benefit Plans with a focus on personalized treatment and empowering employees to effectively manage their health by offering pharmacogenetic testing.
Why offer pharmacogenetic testing in pain and mental health?
Pain and Mental Health Are Two Areas of Critical Need:
More than 40% of plan members suffer from some form of chronic pain, mental health condition, or both 16-18
Pain and mental health are the #1 & #3 drivers of overall healthcare costs and are behind the majority of disability claims 16
58 – 71% have absence days (average 6 – 8 days/year)
51 – 64% arrive late/leave early due to their condition (average 4.7–6.6 times/year)
More than half admit their condition negatively impacts job performance
Up to 70% of those with pain or mental health conditions take medications, and nearly a quarter take 3 or more 16
Pain and mental health conditions are characterized by large variations in individual responses to drugs 19, 20
Up to two-thirds do not respond well to the first treatment initiated, leading to extended periods of trial and error, with chances of remission declining with each new drug trial 21-26
Sub-optimal drug experiences can drive adherence issues and resistance to trying new medications 27
Pain & mental health are closely linked 28-32
Up to 60% of those with chronic pain suffer from mental health conditions like depression and anxiety, and depressed individuals are three times as likely to have chronic pain
Sub optimally treated depression and anxiety amplify pain symptoms & vice versa
There is significant overlap in the medications used to treat these conditions
With few new pain or mental health drugs introduced in recent years, and few in development, "the advancement of pharmacotherapy in the foreseeable future will largely be dependant on drug treatment personalization.” 33
Why offer the Inagene Personalized Insights™ test to your plan
members with pain and/or mental health conditions?
Eliminate trial of drugs that will not work, reducing time spent on drug
"trial and error"
Reduce overall number of drugs used (polypharmacy) and overall drug costs
Minimize absence days and disability
Optimize medication adherence and willingness to try new treatments
Reduce overall medical costs (hospitalizations, expensive interventions and treatments)
Support plan member health, engagement and productivity
Click here to request our package of patient case studies illustrating the value of the Personalized Insights™ Pharmacogenetic Test
Why is Inagene Personalized Insights™ the right pharmacogenetic test to offer to your plan members with pain or mental health conditions?
MOST COMPREHENSIVE IN PAIN & MENTAL HEALTH
Most pharmacogenetic tests evaluate a limited number of variants for each gene impacting medications in pain and mental health. Inagene tests for ALL clinically significant variants occurring in >1/1000 patients (55 genes, 116 variants) to provide the most accurate and complete recommendations.
EXTENSIVE MEDICATIONS TESTED
Our test evaluates more than 130 commonly used medications for pain and mental health conditions (more than any other pharmacogenetic test).
View Medication List
UNPARALLELED QUALITY CONTROL
Personalized Insights™ is the only pharmacogenetic test with a Health Canada MDEL* license, and the only CLIA** accredited pharmacogenetic test in Canada, certifying that it has the validity, accuracy, and reliability to inform clinical care in pain and mental health. Inagene also subscribes to the CAP*** proficiency testing program.
THE BEST VALUE
With Inagene Personalized Insights™ your plan members receive the most comprehensive and reliable test for BOTH pain and mental health at a price that is considerably more affordable than other comparative tests, with no added fees or built-in costs.
COMPREHENSIVE CANNABIS PANEL
Our test includes the most comprehensive genetic panel available for individual response to cannabis and cannabinoids. 25 genes and 68 variants known to impact cannabis metabolism are evaluated, with individualized insights provided regarding optimal strain and dose, and potential for side effects, or cannabis - drug interactions.
THE FASTEST TURN AROUND
Our consumer friendly test kit is ordered online and plan members can complete the test in under 5 minutes. The sample is returned to Inagene by mail in a postage-paid envelope, and a link to access the results is sent within 7 days of receipt at our Toronto based lab.
*MDEL: Medical Device Establishment License
**CLIA (Clinical Laboratory Improvement Amendments) is the governing body that regulates Pgx testing in the USA, certifying tests have the validity, accuracy, and reliability to inform clinical care. CLIA-certification guarantees the most comprehensive, clinically informative test with the highest standard of quality control and test rigour available worldwide.
***CAP: College of American Pathologists
Best-in class report and portal
FAST access to results + EASY Interpretation = LESS delays
Inagene's best in class interactive online report is designed for unparalleled simplicity and convenience and delivered to patients and healthcare providers within 7 days.
Designed for easy comprehension at the consumer level, the report can be easily interpreted and quickly acted on by the patient's own healthcare provider (regardless of pharmacogenetics experience and without mandatory third party interpretation), helping to minimize questions, errors in interpretation, and delays.
Inagene’s secure portal system enables seamless sharing of online reports between plan members and healthcare providers, and enables easy creation of customizable reports and summaries to ensure quick access to the most relevant information.
Inagene's dedicated pharmacists and geneticists are available on demand to offer personalized support throughout the process.
Help your plan members feel better, sooner with less trial and error
Plan members who have had to cycle through drugs know it is frustrating, time-consuming, costly and can worsen their condition.
For organizations, a lack of drug efficacy/tolerability leads to wastage, multiple drug usage, and costly non-drug treatments (therapy, interventional procedures, surgery) and perpetuates absenteeism/disability.
Inagene Personalized Insights™ enables a holistic care plan resulting in a more effective group benefit plan offering for those experiencing mental health issues or chronic pain.
Interested in learning about how Inagene Personalized Insights™ can
help plan members feel better sooner?
Receive the full Information Package for Employers/Benefits Advisors/Insurers (including profiling, reporting, and ROI)
Get added to our emailing list to receive news, updates, and notifications regarding upcoming webinarsAdd Me to the Mailing List
Book a demo of the Personalized Insights™ Report and Portal SystemBook a Demo
1. Broadhead WE, Blazer DG, George LK, Tse CK. Depression, disability days, and days lost from work in a prospective epidemiologic survey. JAMA. 1990;264(19):2524–2528.
2. Simon Ge, VonKorff M, Barlow W. Health care costs of primary care patients with recognized depression. Arch Gen Psychiatry. 1995;52(10): 850–856
3. Smetanin et al. (2011). The life and economic impact of major mental illnesses in Canada: 2011-2041. Prepared for the Mental Health Commission of Canada. Toronto: RiskAnalytica.
4. Lim et al. (2008). A new population-based measure of the burden of mental illness in Canada. Chronic Diseases in Canada, 28: 92-8.
5. Verbelin M et al. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet? The Pharmacogenomics Journal (2017) 17, 395–40
6. Winner J et al. Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1-year prospective evaluation. Current Medical Research & Opinion. Volume 31, 2015 - Issue 9, Pages 1633-1643
7. Maciel , Cullors , Lukowiak , Garces . Estimating cost savings of pharmacogenetic testing for depression in real-world clinical settings. Neuropsychiatr Dis Treat. 2018 Jan 8;14:225-230
8. Chou WH, Yan FX, DeLeon J, et al. Extension of a pilot study: impact from the cytochrome P4502D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol. 2000;20(2):246–251.
9. Kessler RC, Frank RG. The impact of psychiatric disorders on work loss days. Psychol Med. 1997;27(4)
10. Kirsh, K et al. Using Pharmacogenetic Testing in a Pain Practice. Practical Pain management; 2015:l14 (10)
11. Smith et al. CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial. Genetics in medicine. 2019; 21 (8): 1842 – 1850
12. Senagore.A. et al. Pharmacogenetics-guided analgesics in major abdominal surgery: Further benefits within an enhanced recovery protocol. Am J of Surg 213 (2017)
13. Gredin, John et al. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study. Journal of Psychiatric Research. 2019; 111: 59-67
14. Hall – Flavin et al. Using a pharmacogenomic algorithm to guide the treatment of depression. Transl Psychiatry. 2012; Oct; 2 (10)
15. Perlis et al Pharmacogenetic testing among patients with mood and anxiety disorders is associated with decreased utilization and cost: A propensity-score matched study. Depress Anxiety. 2018 Oct;35(10):946-952
16. https://www.sanofi.ca/-/media/Project/One-Sanofi-Web/Websites/North-America/Sanofi-CA/Home/en/Products-and- Resources/sanofi-canada-health-survey/sanofi-canada-healthcare-survey-2020-EN.pdf
17. Mental Health Commission of Canada. (2013). Making the Case for Investing in Mental Health in Canada. http://www.mentalhealthcommission.ca/English/node/5020 ivCanadian Mental Health Association. (2014).
18. Stern.S. et al. Prediction of response to drug therapy in psychiatric disorders. Open Biol. 2018 May; 8(5): 180031 http://angusreid.org/chronic-pain-in-canada/
19. Trescot AM, Faynboym S. A review of the role of genetic testing in pain medicine. Pain Physician. 2014;17(5):425–445.
20. Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going? Van Westrhenen.R. et al. Front. Psychiatry, 12 March 2020
21. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006; 163:28–40
22. Souery D, Serretti A, Calati R, Oswald P, Massat I, Konstantinidis A, et al. Switching antidepressant class does not improve response or remission in treatment-resistant depression. J Clin Psychopharmacol. 2011; 31:512–516
23. Rush A.J. e al.; Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 163(11), 1905-1917 (2006)
24. Thase M.E. et al.; Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta- analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. Int. Clin. Psychopharmacol. 25(4), 189-198 (2010)
25. Moore RA, Straube S, Derry S, et al. Does this work for you? Individuals, averages, and evidence based medicine. BMJ 2008;337:a2585
26. Bandolier. (2007). The Oxford League Table of Analgesic Efficacy. Taken from: http://www.bandolier.org.uk/booth/painpag/Acutrev/Analgesics/Leagtab.html
27. Brown MT et al. Medication adherence – WHO cares? Mayo Clin Proc. 2011 Apr; 86(4): 304–314
28. Kleiber B, Jain S, Trivedi MH. Depression and pain: implications for symptomatic presentation and pharmacological treatments. Psychiatry (Edgmont). 2005;2(5):12-18
29. Gasperi M, Herbert M, Schur E, Buchwald D, Afari N. Genetic and Environmental Influences on Sleep, Pain, and Depression Symptoms in a Community Sample of Twins. Psychosom Med. 2017;79(6):646-654
30. McIntosh AM, Hall LS, Zeng Y, et al. Genetic and Environmental Risk for Chronic Pain and the Contribution of Risk Variants for Major Depressive Disorder: A Family-Based Mixed-Model Analysis. PLoS Med. 2016;13(8)
31. Kleiber B, Jain S, Trivedi MH. Depression and pain: implications for symptomatic presentation and pharmacological treatments. Psychiatry (Edgmont). 2005;2(5):12-18
32. Sheng J, Liu S, Wang Y, Cui R, Zhang X. The Link between Depression and Chronic Pain: Neural Mechanisms in the Brain. Neural Plast. 2017;2017:9724371
33.Ingelman-Sundberg M. Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. New Engl J Med (2008) 358(6):637–9